


SARS-CoV-2 Antibody Assays¹

An important step in the pursuit to understand immunity

Quantitative results to assess persistence and duration of immune response²



ADVIA Centaur® Family



Atellica® Solution



Dimension® Family

Clinical reach with

~20,000

analyzers worldwide³

Up to 440 tests/hour⁴


S1-RBD

SARS-CoV-2 spike protein

**All antibodies are binding;
Only a subset are also neutralizing**

We utilize the spike receptor-binding domain (S1-RBD) antigen to detect neutralizing antibodies that block the virus entry into cells.² This can enable an effective vaccination strategy by assessing the need for and response to vaccination and helping to confirm vaccine efficacy.

Multiple studies estimate antibodies to the S1-RBD comprise ~90% of neutralizing activity.⁵



1. This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary from country to country and is subject to varying regulatory requirements.
2. Some claims are not available in all countries. SARS-CoV-2 IgG (COV2G/CV2G) assays are authorized for semi-quantitative use in the U.S. SARS-CoV-2 Total (COV2T) assays semi-quantitation claim in the U.S. is not available.
3. Installed base of ADVIA Centaur XP, ADVIA Centaur XPT, ADVIA Centaur CP, Atellica Solution, Dimension Vista and Dimension EXL analyzers.
4. Depending on test mix and configuration using Atellica Solution.
5. Piccoli L et al. Cell <https://doi.org/10.1016/j.cell.2020.09.037>